

Masako Sasaki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5803397/publications.pdf>

Version: 2024-02-01

16
papers

354
citations

840776

11
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

590
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of a 3-Pyridylacetic Acid Derivative (TAK-100) as a Potent, Selective and Orally Active Dipeptidyl Peptidase IV (DPP-4) Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 831-850.	6.4	51
2	Design, Synthesis, and Evaluation of Piperazinyl Pyrrolidin-2-ones as a Novel Series of Reversible Monoacylglycerol Lipase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 9205-9217.	6.4	49
3	Design, synthesis, and structure-activity relationships of novel spiro-piperidines as acetyl-CoA carboxylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3643-3647.	2.2	44
4	Symmetrical approach of spiro-pyrazolidinediones as acetyl-CoA carboxylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4769-4772.	2.2	34
5	Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 4482-4498.	3.0	27
6	Discovery of Novel and Potent Stearoyl Coenzyme A Desaturase 1 (SCD1) Inhibitors as Anticancer Agents. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 3768-3779.	3.0	27
7	Design, Synthesis, and Evaluation of (4 <i>R</i>)-1-[3-[2-(¹⁸ F)Fluoro-4-methylpyridin-3-yl]phenyl]-4-[4-(1,3-thiazol-2-ylcarbonyl)piperazin-1-yl]pyrrolidin-2-one (¹⁸ F)-T-401) as a Novel Positron-Emission Tomography Imaging Agent for Monoacylglycerol Lipase. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2362-2375.	6.4	26
8	Discovery of Novel Selective Acetyl-CoA Carboxylase (ACC) 1 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1098-1117.	6.4	18
9	Design and Synthesis of Novel Spiro Derivatives as Potent and Reversible Monoacylglycerol Lipase (MAGL) Inhibitors: Bioisosteric Transformation from 3-Oxo-3,4-dihydro-2 <i>H</i> -benzo[1,4]oxazin-6-yl Moiety. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 11014-11044.	6.4	18
10	In vitro and in vivo antitumor activities of T-3764518, a novel and orally available small molecule stearoyl-CoA desaturase 1 inhibitor. <i>European Journal of Pharmacology</i> , 2017, 807, 21-31.	3.5	16
11	Discovery and characterization of a small-molecule enteropeptidase inhibitor, SCO-792. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00517.	2.4	13
12	Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 379, 280-289.	2.5	11
13	The identification and pharmacological evaluation of potent, selective and orally available ACC1 inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126749.	2.2	8
14	Design and synthesis of a novel 1 <i>H</i> -pyrrolo[3,2- <i>b</i>]pyridine-3-carboxamide derivative as an orally available ACC1 inhibitor. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 2521-2530.	3.0	6
15	Design, Synthesis, and Biological Evaluation of a Novel Series of 4-Guanidinobenzoate Derivatives as Enteropeptidase Inhibitors with Low Systemic Exposure for the Treatment of Obesity. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8456-8477.	6.4	4
16	Design and synthesis of a monocyclic derivative as a selective ACC1 inhibitor by chemical modification of biphenyl ACC1/2 dual inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 35, 116056.	3.0	2